Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$9.69 USD
-0.11 (-1.12%)
Updated Nov 29, 2023 04:00 PM ET
After-Market: $9.68 -0.01 (-0.10%) 5:08 PM ET
3-Hold of 5 3
A Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
TEVA 9.69 -0.11(-1.12%)
Will TEVA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for TEVA
Teva Pharmaceutical Industries Limited (TEVA) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2023 Update
What You Missed On Wall Street This Morning
What You Missed On Wall Street This Morning
Teva raised to Buy at UBS on brand transition